| 251 |
15248926 | [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer]. | 2004 Jul |
3 |
| 252 |
15277258 | Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. | 2004 Aug |
4 |
| 253 |
15375562 | Confirmation of 42-bp deletion within the ERCC1 5' UTR. | 2004 Oct |
1 |
| 254 |
15547660 | Excision repair cross complementing-group 1: gene expression and platinum resistance. | 2004 Dec |
1 |
| 255 |
12504621 | Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. | 2003 Jan |
1 |
| 256 |
12649192 | Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. | 2003 Mar 15 |
5 |
| 257 |
12867068 | Genetic testing for chemotherapy in non-small cell lung cancer. | 2003 Aug |
1 |
| 258 |
12915808 | Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. | 2003 Jul-Aug |
3 |
| 259 |
12917817 | Targeted therapy in combination with gemcitabine in non-small cell lung cancer. | 2003 Aug |
2 |
| 260 |
14624713 | Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. | 2003 Jan |
1 |
| 261 |
14668933 | Influence of genetic markers on survival in non-small cell lung cancer. | 2003 Oct |
2 |
| 262 |
12023789 | Pemetrexed combination therapy in the treatment of non-small cell lung cancer. | 2002 Apr |
1 |
| 263 |
12114432 | Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. | 2002 Jul |
11 |
| 264 |
12359362 | Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression. | 2002 Dec 10 |
1 |
| 265 |
12437479 | Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. | 2002 Nov |
1 |
| 266 |
12445742 | DNA repair and cisplatin resistance in non-small-cell lung cancer. | 2002 Dec |
2 |
| 267 |
12480194 | Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. | 2002 Dec |
1 |
| 268 |
11163512 | An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin. | 2001 Jan 1 |
5 |
| 269 |
11605182 | Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. | 2001 Aug |
1 |
| 270 |
11761458 | In vitro studies on the mechanisms of oxaliplatin resistance. | 2001 Nov |
1 |
| 271 |
10675489 | Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. | 2000 Mar |
1 |
| 272 |
10741696 | Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. | 2000 Mar |
1 |
| 273 |
10810335 | Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. | 2000 Mar-Apr |
9 |
| 274 |
11008124 | Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. | 2000 Nov 1 |
3 |
| 275 |
11008128 | Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. | 2000 Nov 1 |
1 |
| 276 |
11008208 | ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. | 2000 Sep 20 |
6 |
| 277 |
11589365 | Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. | 2000 May-Jun |
5 |
| 278 |
9933022 | Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. | 1999 Feb 15 |
4 |
| 279 |
9440758 | ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. | 1998 Jan |
2 |
| 280 |
9703867 | Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. | 1998 Jul-Aug |
6 |
| 281 |
9722577 | Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. | 1998 Sep 4 |
3 |
| 282 |
9772291 | Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. | 1998 Nov |
5 |
| 283 |
9852275 | Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. | 1998 Mar |
1 |
| 284 |
21597714 | Expression of an alternatively spliced ercc1 messenger-RNA species, is related to reduced DNA-repair efficiency in human T-lymphocytes. | 1995 Mar |
2 |
| 285 |
7923602 | Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity. | 1994 Sep |
2 |
| 286 |
8065913 | Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. | 1994 Aug 11 |
1 |
| 287 |
8222071 | Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. | 1993 Oct |
1 |